Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 1, 2013, Pages 150-157

  Vater, A ^a   Sahlmann, J ^b   Kroger N ^c   Zollner S ^a   Lioznov, M ^c   Maasch, C ^a   Buchner, K ^a   Vossmeyer, D ^a   Schwoebel, F ^a   Purschke, W G ^a   Vonhoff, S ^a   Kruschinski, A ^a   Hubel K ^d   Humphrey, M ^a   Klussmann, S ^a   Fliegert, F ^a  

^a NOXXON PHARMA AG   (Germany)

^b Scope International GmbH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL2 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; NOX A12; OLIGONUCLEOTIDE; PLERIXAFOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; FEMALE; HAPLORHINI; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANIMALS; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MACACA; MALE; MICE; MIDDLE AGED; MODELS, ANIMAL; OLIGONUCLEOTIDES; YOUNG ADULT;

EID: 84879415568     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.58     Document Type: Article

References (30)

1. Nagasawa, T., Kikutani, H. & Kishimoto, T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. U.S.A. 91, 2305-2309 (1994).
2. Zagzag, D. et al. Hypoxia-and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am. J. Pathol. 173, 545-560 (2008).
3. Kucia, M. et al. Trafcking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894 (2005).
4. Ma, Q. et al. impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-defcient mice. Proc. Natl. Acad. Sci. U.S.A. 95, 9448-9453 (1998).
5. Aiuti, A., Webb, I.J., Bleul, C., Springer, T. & Gutierrez-Ramos, J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185, 111-120 (1997).
6. Hoggatt, J. & Pelus, L.M. Mobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment. Stem Cell Res. Ther. 2, 13 (2011).
7. Broxmeyer, H.E. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307-1318 (2005).
8. Food and Drug Administration. Mozobil prescribing information, NDA022311. (2010).
9. Alsayed, Y. et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109, 2708-2717 (2007).
10. Domanska, U.M. et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur. J. Cancer 49, 219-230 (2013).
11. Burns, J.M. et al. A novel chemokine receptor for SDF-1 and i-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201-2213 (2006).
12. Miao, Z. et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U.S.A. 104, 15735-15740 (2007).
13. Hattermann, K. et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic efects. Cancer Res. 70, 3299-3308 (2010).
14. Azab, A.K. et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341-4351 (2009).
15. Duda, D.G., Kozin, S.V., Kirkpatrick, N.D., Xu, L., Fukumura, D. & Jain, R.K. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 17, 2074-2080 (2011).
16. Tavor, S. & Petit, i. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin. Cancer Biol. 20, 178-185 (2010).
17. Klussmann, S., Nolte, A., Bald, R., Erdmann, V.A. & Fürste, J.P. Mirror-image RNA that binds D-adenosine. Nat. Biotechnol. 14, 1112-1115 (1996).
18. Keefe, A.D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550 (2010).
19. Yu, L. et al. identifcation and expression of novel isoforms of human stromal cell-derived factor 1. Gene 374, 174-179 (2006).
20. Boisgard, R. et al. In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 32, 470-477 (2005).
21. Webster, R., Elliott, V., Park, B.K., Walker, D., Hankin, M. & Taupin, P. PEGylated protein drugs: basic science and clinical application. in PEG and PEG Conjugates Toxicity: Towards an Understanding of the Toxicity of PEG and Its Relevance to PEGylated Biologicals, (eds. Veronese, F.M. & Mero, A.) 127-146 Birkhäuser Verlag, Basel, (2009).
22. Hübel, K. et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support. Cancer Ther. 1, 165-172 (2004).
23. Devine, S.M. et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112, 990-998 (2008).
24. Liles, W.C. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728-2730 (2003).
25. To, L.B., Haylock, D.N., Simmons, P.J. & Juttner, C.A. The biology and clinical uses of blood stem cells. Blood 89, 2233-2258 (1997).
26. Dar, A. et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 25, 1286-1296 (2011).
27. Ratajczak, M.Z. et al. A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia 26, 63-72 (2012)
28. Kryczek, I. et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65, 465-472 (2005).
29. Burger, J.A. & Peled, A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23, 43-52 (2009).
30. Keeney, M., Gratama, J.W. & Sutherland, D.R. Critical role of fow cytometry in evaluating peripheral blood hematopoietic stem cell grafts. Cytometry. A 58, 72-75 (2004).